76 related articles for article (PubMed ID: 19089462)
1. Warfarin and bisphosphontes interaction in patients undergoing total knee arthroplasty.
Al-Shwilly AAH; Al-Shwilly HAJ; Kadhim HH
J Orthop; 2024 Mar; 49():33-37. PubMed ID: 38090601
[TBL] [Abstract][Full Text] [Related]
2. Preparation, Characterization, and Preliminary Imaging Study of [
Xu T; Wang Y; Chen Z; Liu H; Yang S; Liu G; Zhao Y; Fu W; Liu L; Xiang K; Peng D; Chen Y
Contrast Media Mol Imaging; 2022; 2022():7684076. PubMed ID: 35280705
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate nephropathy: A case series and review of the literature.
de Roij van Zuijdewijn C; van Dorp W; Florquin S; Roelofs J; Verburgh K
Br J Clin Pharmacol; 2021 Sep; 87(9):3485-3491. PubMed ID: 33595131
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.
Shibata H; Kato S; Sekine I; Abe K; Araki N; Iguchi H; Izumi T; Inaba Y; Osaka I; Kato S; Kawai A; Kinuya S; Kodaira M; Kobayashi E; Kobayashi T; Sato J; Shinohara N; Takahashi S; Takamatsu Y; Takayama K; Takayama K; Tateishi U; Nagakura H; Hosaka M; Morioka H; Moriya T; Yuasa T; Yurikusa T; Yomiya K; Yoshida M
ESMO Open; 2016; 1(2):e000037. PubMed ID: 27843593
[TBL] [Abstract][Full Text] [Related]
5. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
[TBL] [Abstract][Full Text] [Related]
6. Local application of ibandronate/gelatin sponge improves osteotomy healing in rabbits.
Yang Z; Chen W; Xia Z; Liu Y; Peggrem S; Geng T; Yang Z; Li H; Xu B; Zhang C; Triffitt JT; Zhang Y
PLoS One; 2015; 10(5):e0125807. PubMed ID: 25951178
[TBL] [Abstract][Full Text] [Related]
7. Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature.
Rahbari-Oskoui F; Fielder O; Ghasemzadeh N; Hennigar R
Case Rep Nephrol; 2013; 2013():651246. PubMed ID: 24527249
[TBL] [Abstract][Full Text] [Related]
8. Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis.
Fidan E; Yildiz B; Kavgaci H; Ozdemir F; Aydin F
Contemp Oncol (Pozn); 2012; 16(2):176-8. PubMed ID: 23788873
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.
Schmitt S; Hielscher T; Baldus C; Neben K; Egerer G; Hillengaß J; Raab M; Hose D; Ho AD; Bergner R; Goldschmidt H; Moehler TM
Int J Hematol; 2013 Jun; 97(6):765-72. PubMed ID: 23616219
[TBL] [Abstract][Full Text] [Related]
10. Changes in renal function after different tandem hematopoietic stem-cell transplantation approaches in patients with multiple myeloma.
Kang SH; Hwang HS; Park HS; Sun IO; Choi SR; Chung BH; Choi BS; Yang CW; Kim YS; Min CK; Park CW
J Korean Med Sci; 2011 Oct; 26(10):1310-5. PubMed ID: 22022183
[TBL] [Abstract][Full Text] [Related]
11. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
Shah SR; Jean GW; Keisner SV; Ussery SM; Dowell JE
Support Care Cancer; 2012 Jan; 20(1):87-93. PubMed ID: 21197550
[TBL] [Abstract][Full Text] [Related]
12. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
13. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Lipton A; Uzzo R; Amato RJ; Ellis GK; Hakimian B; Roodman GD; Smith MR
J Natl Compr Canc Netw; 2009 Oct; 7 Suppl 7(Suppl 7):S1-29; quiz S30. PubMed ID: 19878635
[TBL] [Abstract][Full Text] [Related]
14. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
[TBL] [Abstract][Full Text] [Related]
15. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
[TBL] [Abstract][Full Text] [Related]
16. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
18. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
